ArticlePakistan journal of medical sciences2025
Clinical effects of chemotherapy combined with Bevacizumab and Olaparib in treating advanced ovarian cancer and its effect on serum tumor markers and T-lymphocyte functions.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the clinical efficacy of chemotherapy combined with bevacizumab and olaparib in treating advanced ovarian cancer and investigate the effect of such combination treatment on serum tumor markers and T-lymphocyte function. Methods: This was a retrospective study. A total of 120 patients with advanced ovarian cancer admitted to Baoding Second Hospital and Baoding First Central Hospital from January 2022 to June 2024 were randomly divided into two groups(n= 60 each group): the control group received standard paclitaxel and carboplatin chemotherapy(TP regimen), while the study group was administered bevacizumab infusions and oral olaparib, in addition to the exact treatment provided for the control group. Comparisons were made between the two groups regarding the clinical efficacy and adverse drug reactions. Results: The overall response rate was 92% and 68% in the study group and the control group, respectively, suggesting a difference of statistical significance( Conclusion: The combined use of conventional chemotherapy, bevacizumab, and olaparib demonstrates significant clinical efficacy in the treatment of advanced ovarian cancer, which can improve cellular immune function, lower tumor marker levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.